News

November 20, 2015 9:15 am
Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.
November 20, 2015 9:15 am
IMF Chairman Dr. Brian Durie will present “Myeloma 101: Updates on Treatment & Pain Management” during this informative teleconference, and will shed light on the most up-to-date therapies for myeloma patients.
November 20, 2015 9:15 am
First Irreversible Proteasome Inhibitor for Relapsed Multiple Myeloma Approved in the European Union. Approval Based on Data From Pivotal Phase 3 ASPIRE Trial Which Demonstrated Patients Treated With Kyprolis in Combination Lived Nearly Nine Months...
November 16, 2015 11:45 am
Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for...

Pages